Control of preventive chemotherapy-targeted neglected tropical diseases (PC-NTDs) depends on strengthened health techniques. Efficient health data techniques present an impetus to reaching the sustainable growth aim geared toward ending PC-NTD epidemics. However, there’s restricted evaluation of surveillance system capabilities linked to PC-NTDs and hinged on optimum efficiency of surveillance system attributes. The examine aimed to guage surveillance system attributes based mostly on healthcare staff’ perceptions in relation to PC-NTDs endemic in Kenya. A cross-sectional health facility survey was used to purposively pattern respondents concerned in illness surveillance actions.
Consenting respondents accomplished a self-administered questionnaire that assessed their perceptions on surveillance system attributes on a five-point likert scale. Frequency distributions for every level in the likert scale had been analysed to find out health staff’ general perceptions. Data was analysed utilizing descriptive statistics and estimated median values with corresponding interquartile ranges used to summarise reporting charges. Factor evaluation recognized variables measuring particular latent attributes. Pearson’s chi-square and Fisher’s precise checks examined associations between categorical variables. Thematic evaluation was carried out for questionnaire open-ended responses.
Most (88%) respondents labored in public health amenities with 71% stationed in second-tier amenities. Regarding PC-NTDs, respondents perceived the surveillance system to be easy (55%), acceptable (50%), secure (41%), versatile (41%), helpful (51%) and to supply high quality knowledge (25%). Facility locality, facility sort, respondents’ schooling stage and years of work expertise had been related to perceived opinion on acceptability and stability respectively. Median month-to-month reporting timeliness and completeness charges for amenities had been 75 (58.3, 83.3) and 83.Three respectively.
Higher-level amenities met reporting timeliness (p < 0.001) and completeness (p < 0.001) thresholds in comparison with lower-level amenities. Health personnel had decrease perceptions on the stability, flexibility and knowledge high quality of the surveillance system contemplating PC-NTDs. Reporting timeliness and completeness charges decreased in 2017 in comparison with earlier surveillance intervals. Strengthening all surveillance capabilities would affect health staff’ perceptions and enhance surveillance system general efficiency with regard to PC-NTDs.
An Overview of Current Uses and Future Opportunities for Computer-Assisted Design of Vaccines for Neglected Tropical Diseases
Neglected tropical diseases are infectious diseases that impose excessive morbidity and mortality charges over 1.5 billion individuals worldwide. Originally restricted to tropical and subtropical areas, altering local weather circumstances have elevated their potential to emerge elsewhere. Control of their impression suffers from shortages like poor epidemiological surveillance or irregular drug distribution, and a few NTDs nonetheless lack of acceptable diagnostics and/or environment friendly therapeutics. For these, availability of vaccines to forestall new infections, or the worsening of these already established, would imply a significant breakthrough.
However, solely dengue and rabies rely with permitted vaccines at current. Herein, we evaluate the state-of-the-art of vaccination methods for NTDs, setting the deal with third technology vaccines and the idea of reverse vaccinology. Its functionality to handle pathogens´ organic complexity, seemingly contributing to save lots of developmental prices is mentioned. The use of computational instruments is a elementary assist to research more and more massive datasets geared toward designing vaccine candidates with the highest, probably, alternatives to succeed. Ultimately, we determine and analyze these research that took an in silico method to search out vaccine candidates, and experimentally assessed their immunogenicity and/or safety capabilities.
Neglected tropical diseases (NTDs) are a various group of communicable diseases that principally impression the world’s poorest individuals. The use of digital health applied sciences is an rising and promising manner to enhance illness prevention, prognosis, case detection, therapy supply, and affected person follow-up and facilitating health facility appointments thereby bettering health outcomes. While the rising implementation of digital health applied sciences is clear, there’s a lack of complete proof on the impression of digital health applied sciences in the management of NTDs. The important goal of this evaluate was to map totally different items of proof on the use of digital health applied sciences for case detection, administration, and therapy end result of the neglected tropical illness.
Rethinking neglected tropical illness prevalence survey design and evaluation: a geospatial paradigm
Current strategies for the design and evaluation of neglected tropical illness prevalence surveys largely depend on classical survey sampling concepts that deal with prevalence knowledge from totally different places as an impartial random pattern from the chance distribution induced by a random sampling design. We set out an alternate, explicitly geospatial paradigm that may ship far more exact estimates of the geospatial variation in prevalence over a rustic or area of curiosity. We describe the benefits of this method below three headings: streamlining, whereby extra exact outcomes may be obtained with smaller pattern sizes; integrating, whereby a joint evaluation of knowledge from two or extra diseases can convey additional positive aspects in precision; and adapting, whereby the selection of future sampling location is knowledgeable by previous knowledge.
 AZI2 Antibody |
|
34065-100ul |
SAB |
100ul |
EUR 252 |
AZI2 Antibody |
|
34065-50ul |
SAB |
50ul |
EUR 187 |
AZI2 Antibody |
|
1-CSB-PA003368 |
Cusabio |
|
|
- Form: Liquid
- Buffer: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
|
|
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/20000 |
AZI2 Antibody |
|
CSB-PA596738- |
Cusabio |
|
EUR 335 |
- Form: liquid
- Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific
- Show more
|
|
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
AZI2 Antibody |
|
CSB-PA596738-100ul |
Cusabio |
100ul |
EUR 316 |
- Form: liquid
- Buffer: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific
- Show more
|
|
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
AZI2 Antibody |
|
1-CSB-PA863992LA01HU |
Cusabio |
|
|
- Form: Liquid
- Buffer: Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
|
|
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC, IF; Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200 |
AZI2 Antibody |
|
DF3437 |
Affbiotech |
200ul |
EUR 304 |
|
Description: AZI2 Antibody detects endogenous levels of total AZI2. |
AZI2 Antibody |
|
AF0553 |
Affbiotech |
200ul |
EUR 304 |
|
Description: AZI2 Antibody detects endogenous levels of AZI2. |
 Anti-AZI2 Antibody |
|
A08235 |
BosterBio |
100ul |
EUR 397 |
|
Description: Rabbit Polyclonal AZI2 Antibody. Validated in WB and tested in Human, Mouse, Rat. |
 AZI2 Conjugated Antibody |
|
C34065 |
SAB |
100ul |
EUR 397 |
 anti- AZI2 antibody |
|
FNab00758 |
FN Test |
100µg |
EUR 505.25 |
- Recommended dilution: WB: 1:500-1:2000
- IHC: 1:20-1:200
- Immunogen: 5-azacytidine induced 2
- Uniprot ID: Q9H6S1
- Gene ID: 64343
- Research Area: Developmental biology
|
|
Description: Antibody raised against AZI2 |
 AZI2 siRNA |
|
20-abx900565 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
AZI2 siRNA |
|
20-abx908745 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
AZI2 siRNA |
|
20-abx908746 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
 AZI2 Antibody, HRP conjugated |
|
1-CSB-PA863992LB01HU |
Cusabio |
|
|
- Form: Liquid
- Buffer: Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
|
|
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA |
 AZI2 Antibody, FITC conjugated |
|
1-CSB-PA863992LC01HU |
Cusabio |
|
|
- Form: Liquid
- Buffer: Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
|
|
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA |
 AZI2 Antibody, Biotin conjugated |
|
1-CSB-PA863992LD01HU |
Cusabio |
|
|
- Form: Liquid
- Buffer: Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4 >95%, Protein G purified
|
|
Description: A polyclonal antibody against AZI2. Recognizes AZI2 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA |
 AZI2 Blocking Peptide |
|
DF3437-BP |
Affbiotech |
1mg |
EUR 195 |
AZI2 Blocking Peptide |
|
AF0553-BP |
Affbiotech |
1mg |
EUR 195 |
 Rat AZI2 shRNA Plasmid |
|
20-abx989925 |
Abbexa |
|
|
- Shipped within 15-20 working days.
|
 Mouse AZI2 shRNA Plasmid |
|
20-abx973842 |
Abbexa |
|
|
- Shipped within 15-20 working days.
|
 Human AZI2 shRNA Plasmid |
|
20-abx961990 |
Abbexa |
|
|
- Shipped within 15-20 working days.
|
) AZI2 Recombinant Protein (Human) |
|
RP048181 |
ABM |
100 ug |
Ask for price |
) AZI2 Recombinant Protein (Mouse) |
|
RP118415 |
ABM |
100 ug |
Ask for price |
AZI2 Recombinant Protein (Mouse) |
|
RP118418 |
ABM |
100 ug |
Ask for price |
) AZI2 Recombinant Protein (Rat) |
|
RP191693 |
ABM |
100 ug |
Ask for price |
 Antibody) 5-Azacytidine-Induced Protein 2 (AZI2) Antibody |
|
20-abx013797 |
Abbexa |
-
EUR 314.00
-
EUR 98.00
-
EUR 398.00
-
EUR 495.00
|
-
100 ug
-
10 ug
-
200 ug
-
300 µg
|
- Shipped within 5-10 working days.
|
5-Azacytidine-Induced Protein 2 (AZI2) Antibody |
|
20-abx329457 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
5-Azacytidine-Induced Protein 2 (AZI2) Antibody |
|
abx332767-100ul |
Abbexa |
100 ul |
EUR 425 |
- Shipped within 5-10 working days.
|
5-Azacytidine-Induced Protein 2 (AZI2) Antibody |
|
20-abx333820 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
- Shipped within 5-10 working days.
|
5-Azacytidine-Induced Protein 2 (AZI2) Antibody |
|
abx230758-100ug |
Abbexa |
100 ug |
EUR 481 |
- Shipped within 5-12 working days.
|
 (pORF)) Azi2 ORF Vector (Rat) (pORF) |
|
ORF063899 |
ABM |
1.0 ug DNA |
EUR 506 |
 (pORF)) AZI2 ORF Vector (Human) (pORF) |
|
ORF016061 |
ABM |
1.0 ug DNA |
Ask for price |
 (pORF)) Azi2 ORF Vector (Mouse) (pORF) |
|
ORF039473 |
ABM |
1.0 ug DNA |
EUR 506 |
Azi2 ORF Vector (Mouse) (pORF) |
|
ORF039474 |
ABM |
1.0 ug DNA |
EUR 506 |
 (OKEH07990)) AZI2 ELISA Kit (Human) (OKEH07990) |
|
OKEH07990 |
Aviva Systems Biology |
96 Wells |
EUR 896 |
|
Description: Description of target: AZI2, or NAP1, contributes to the activation of NFKB (see MIM 164011)-dependent gene expression by activating IKK-related kinases, such as NAK (TBK1; MIM 604834) (Fujita et al., 2003 [PubMed 14560022]).[supplied by OMIM, Mar 2008];Species reactivity: Human;Application: ELISA;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.093ng/mL |
 Antibody (HRP)) 5-Azacytidine-Induced Protein 2 (AZI2) Antibody (HRP) |
|
20-abx334503 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
- Shipped within 5-10 working days.
|
 Antibody (FITC)) 5-Azacytidine-Induced Protein 2 (AZI2) Antibody (FITC) |
|
20-abx334504 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
- Shipped within 5-10 working days.
|
 Antibody (Biotin)) 5-Azacytidine-Induced Protein 2 (AZI2) Antibody (Biotin) |
|
20-abx334505 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
- Shipped within 5-10 working days.
|
) Azi2 sgRNA CRISPR Lentivector set (Rat) |
|
K7135801 |
ABM |
3 x 1.0 ug |
EUR 339 |
) Azi2 sgRNA CRISPR Lentivector set (Mouse) |
|
K3190301 |
ABM |
3 x 1.0 ug |
EUR 339 |
) AZI2 sgRNA CRISPR Lentivector set (Human) |
|
K0162101 |
ABM |
3 x 1.0 ug |
EUR 339 |
 (Target 1)) Azi2 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|
K7135802 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 2)) Azi2 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|
K7135803 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 3)) Azi2 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|
K7135804 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 1)) Azi2 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|
K3190302 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 2)) Azi2 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|
K3190303 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 3)) Azi2 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|
K3190304 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 1)) AZI2 sgRNA CRISPR Lentivector (Human) (Target 1) |
|
K0162102 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 2)) AZI2 sgRNA CRISPR Lentivector (Human) (Target 2) |
|
K0162103 |
ABM |
1.0 ug DNA |
EUR 154 |
 (Target 3)) AZI2 sgRNA CRISPR Lentivector (Human) (Target 3) |
|
K0162104 |
ABM |
1.0 ug DNA |
EUR 154 |
 (pPB-C-His)) AZI2 Protein Vector (Mouse) (pPB-C-His) |
|
PV157890 |
ABM |
500 ng |
EUR 603 |
 (pPB-N-His)) AZI2 Protein Vector (Mouse) (pPB-N-His) |
|
PV157891 |
ABM |
500 ng |
EUR 603 |
 (pPM-C-HA)) AZI2 Protein Vector (Mouse) (pPM-C-HA) |
|
PV157892 |
ABM |
500 ng |
EUR 603 |
 (pPM-C-His)) AZI2 Protein Vector (Mouse) (pPM-C-His) |
|
PV157893 |
ABM |
500 ng |
EUR 603 |
AZI2 Protein Vector (Mouse) (pPB-C-His) |
|
PV157894 |
ABM |
500 ng |
EUR 603 |
AZI2 Protein Vector (Mouse) (pPB-N-His) |
|
PV157895 |
ABM |
500 ng |
EUR 603 |
AZI2 Protein Vector (Mouse) (pPM-C-HA) |
|
PV157896 |
ABM |
500 ng |
EUR 603 |
AZI2 Protein Vector (Mouse) (pPM-C-His) |
|
PV157897 |
ABM |
500 ng |
EUR 603 |
 (pPB-C-His)) AZI2 Protein Vector (Rat) (pPB-C-His) |
|
PV255594 |
ABM |
500 ng |
EUR 603 |
 (pPB-N-His)) AZI2 Protein Vector (Rat) (pPB-N-His) |
|
PV255595 |
ABM |
500 ng |
EUR 603 |
 (pPM-C-HA)) AZI2 Protein Vector (Rat) (pPM-C-HA) |
|
PV255596 |
ABM |
500 ng |
EUR 603 |
 (pPM-C-His)) AZI2 Protein Vector (Rat) (pPM-C-His) |
|
PV255597 |
ABM |
500 ng |
EUR 603 |
 (pPB-His-MBP)) AZI2 Protein Vector (Human) (pPB-His-MBP) |
|
PV325866 |
ABM |
500 ng |
Ask for price |
 (pPB-His-GST)) AZI2 Protein Vector (Human) (pPB-His-GST) |
|
PV325867 |
ABM |
500 ng |
Ask for price |
 (pPB-C-His)) AZI2 Protein Vector (Human) (pPB-C-His) |
|
PV064241 |
ABM |
500 ng |
Ask for price |
 (pPB-N-His)) AZI2 Protein Vector (Human) (pPB-N-His) |
|
PV064242 |
ABM |
500 ng |
Ask for price |
 (pPM-C-HA)) AZI2 Protein Vector (Human) (pPM-C-HA) |
|
PV064243 |
ABM |
500 ng |
Ask for price |
 (pPM-C-His)) AZI2 Protein Vector (Human) (pPM-C-His) |
|
PV064244 |
ABM |
500 ng |
Ask for price |
 Azi2 3'UTR GFP Stable Cell Line |
|
TU152443 |
ABM |
1.0 ml |
Ask for price |
 Azi2 3'UTR Luciferase Stable Cell Line |
|
TU102443 |
ABM |
1.0 ml |
Ask for price |
Azi2 3'UTR Luciferase Stable Cell Line |
|
TU201164 |
ABM |
1.0 ml |
Ask for price |
Azi2 3'UTR GFP Stable Cell Line |
|
TU251164 |
ABM |
1.0 ml |
Ask for price |
 AZI2 3'UTR GFP Stable Cell Line |
|
TU051559 |
ABM |
1.0 ml |
EUR 1521 |
 AZI2 3'UTR Luciferase Stable Cell Line |
|
TU001559 |
ABM |
1.0 ml |
EUR 1521 |
 (CMV) (pLenti-GIII-CMV)) AZI2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV652339 |
ABM |
1.0 ug DNA |
EUR 682 |
 (UbC) (pLenti-GIII-UbC)) AZI2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV652343 |
ABM |
1.0 ug DNA |
EUR 682 |
 (EF1a) (pLenti-GIII-EF1a)) AZI2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV652344 |
ABM |
1.0 ug DNA |
EUR 682 |
 ELISA Kit) Human 5-Azacytidine-Induced Protein 2 (AZI2) ELISA Kit |
|
abx385978-96tests |
Abbexa |
96 tests |
EUR 754 |
- Shipped within 20 working days.
|
 Bovine 5- azacytidine- induced protein 2, AZI2 ELISA KIT |
|
ELI-34726b |
Lifescience Market |
96 Tests |
EUR 928 |
 Human 5- azacytidine- induced protein 2, AZI2 ELISA KIT |
|
ELI-49615h |
Lifescience Market |
96 Tests |
EUR 824 |
 Mouse 5- azacytidine- induced protein 2, Azi2 ELISA KIT |
|
ELI-50028m |
Lifescience Market |
96 Tests |
EUR 865 |
 (pPM-N-D-C-HA)) AZI2 Protein Vector (Human) (pPM-N-D-C-HA) |
|
PV325868 |
ABM |
500 ng |
Ask for price |
 (pPM-N-D-C-His)) AZI2 Protein Vector (Human) (pPM-N-D-C-His) |
|
PV325869 |
ABM |
500 ng |
Ask for price |
) Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|
K7135805 |
ABM |
3 x 1.0 ug |
EUR 376 |
) Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|
K3190305 |
ABM |
3 x 1.0 ug |
EUR 376 |
) AZI2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|
K0162105 |
ABM |
3 x 1.0 ug |
EUR 376 |
 (CMV) (pLenti-GIII-CMV-C-term-HA)) AZI2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV652340 |
ABM |
1.0 ug DNA |
EUR 682 |
 (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)) AZI2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV652341 |
ABM |
1.0 ug DNA |
EUR 740 |
 (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)) AZI2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV652342 |
ABM |
1.0 ug DNA |
EUR 740 |
 (Target 1)) Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|
K7135806 |
ABM |
1.0 ug DNA |
EUR 167 |
 (Target 2)) Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|
K7135807 |
ABM |
1.0 ug DNA |
EUR 167 |
 (Target 3)) Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|
K7135808 |
ABM |
1.0 ug DNA |
EUR 167 |
 (Target 1)) Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|
K3190306 |
ABM |
1.0 ug DNA |
EUR 167 |
 (Target 2)) Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|
K3190307 |
ABM |
1.0 ug DNA |
EUR 167 |
 (Target 3)) Azi2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|
K3190308 |
ABM |
1.0 ug DNA |
EUR 167 |
 (Target 1)) AZI2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|
K0162106 |
ABM |
1.0 ug DNA |
EUR 167 |
 (Target 2)) AZI2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|
K0162107 |
ABM |
1.0 ug DNA |
EUR 167 |
 (Target 3)) AZI2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|
K0162108 |
ABM |
1.0 ug DNA |
EUR 167 |
 H2B Antibody Antibody |
|
AF4659 |
Affbiotech |
200ul |
EUR 376 |
|
Description: H2B Antibody Antibody detects endogenous levels of H2B. |
 anti- Antibody^Polyclonal antibody control antibody |
|
LSMab09882 |
Lifescience Market |
100 ug |
EUR 438 |
 Antibody) Ly1 Antibody Reactive (LYAR) Antibody |
|
20-abx008109 |
Abbexa |
-
EUR 300.00
-
EUR 439.00
-
EUR 189.00
|
|
- Shipped within 5-10 working days.
|
 Antibody) Anti-Glycolipid Antibody (AGA) Antibody |
|
20-abx004855 |
Abbexa |
-
EUR 411.00
-
EUR 592.00
-
EUR 182.00
-
EUR 314.00
|
-
100 ul
-
200 ul
-
20 ul
-
50 ul
|
- Shipped within 5-10 working days.
|
Ly1 Antibody Reactive (LYAR) Antibody |
|
20-abx123734 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
Anti-Glycolipid Antibody (AGA) Antibody |
|
abx036399-100ug |
Abbexa |
100 ug |
EUR 391 |
- Shipped within 5-10 working days.
|
Ly1 Antibody Reactive (LYAR) Antibody |
|
20-abx014333 |
Abbexa |
-
EUR 314.00
-
EUR 98.00
-
EUR 398.00
-
EUR 495.00
|
-
100 ug
-
10 ug
-
200 ug
-
300 µg
|
- Shipped within 5-10 working days.
|
Ly1 Antibody Reactive (LYAR) Antibody |
|
abx033330-400ul |
Abbexa |
400 ul |
EUR 523 |
- Shipped within 5-10 working days.
|
Ly1 Antibody Reactive (LYAR) Antibody |
|
abx033330-80l |
Abbexa |
80 µl |
EUR 286 |
- Shipped within 5-10 working days.
|
 Antibody) Anti-Glycoprotein Antibody (GP) Antibody |
|
20-abx319900 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
- Shipped within 5-10 working days.
|
Anti-Glycoprotein Antibody (GP) Antibody |
|
20-abx319901 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
- Shipped within 5-10 working days.
|
Anti-Glycoprotein Antibody (GP) Antibody |
|
20-abx319905 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
- Shipped within 5-10 working days.
|
Anti-Glycoprotein Antibody (GP) Antibody |
|
20-abx319913 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
- Shipped within 5-10 working days.
|
Ly1 Antibody Reactive (LYAR) Antibody |
|
abx234901-100ug |
Abbexa |
100 ug |
EUR 551 |
- Shipped within 5-12 working days.
|
Ly1 Antibody Reactive (LYAR) Antibody |
|
20-abx324434 |
Abbexa |
|
|
- Shipped within 5-10 working days.
|
Ly1 Antibody Reactive (LYAR) Antibody |
|
20-abx311665 |
Abbexa |
-
EUR 411.00
-
EUR 1845.00
-
EUR 599.00
-
EUR 182.00
-
EUR 300.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
- Shipped within 5-10 working days.
|
Anti-Glycolipid Antibody (AGA) Antibody |
|
abx230204-100ug |
Abbexa |
100 ug |
EUR 481 |
- Shipped within 5-12 working days.
|
 Anti-Anti-SEPT6 antibody antibody |
|
STJ11100949 |
St John's Laboratory |
100 µl |
EUR 277 |
|
Description: This gene is a member of the septin family of GTPases. Members of this family are required for cytokinesis. One version of pediatric acute myeloid leukemia is the result of a reciprocal translocation between chromosomes 11 and X, with the breakpoint associated with the genes encoding the mixed-lineage leukemia and septin 2 proteins. This gene encodes four transcript variants encoding three distinct isoforms. An additional transcript variant has been identified, but its biological validity has not been determined. |
 Anti-Anti-SEPT9 Antibody antibody |
|
STJ111369 |
St John's Laboratory |
100 µl |
EUR 277 |
|
Description: This gene is a member of the septin family involved in cytokinesis and cell cycle control. This gene is a candidate for the ovarian tumor suppressor gene. Mutations in this gene cause hereditary neuralgic amyotrophy, also known as neuritis with brachial predilection. A chromosomal translocation involving this gene on chromosome 17 and the MLL gene on chromosome 11 results in acute myelomonocytic leukemia. Multiple alternatively spliced transcript variants encoding different isoforms have been described. |
 Anti-Anti-SEPT4 Antibody antibody |
|
STJ112276 |
St John's Laboratory |
100 µl |
EUR 277 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is highly expressed in brain and heart. Alternatively spliced transcript variants encoding different isoforms have been described for this gene. One of the isoforms (known as ARTS) is distinct; it is localized to the mitochondria, and has a role in apoptosis and cancer. |
 Anti-Anti-SEPT5 Antibody antibody |
|
STJ25477 |
St John's Laboratory |
100 µl |
EUR 277 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
 Anti-Anti-SEPT8 Antibody antibody |
|
STJ25479 |
St John's Laboratory |
100 µl |
EUR 277 |
|
Description: This gene is a member of the septin family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse, and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
 Anti-Anti-SEPT7 Antibody antibody |
|
STJ28963 |
St John's Laboratory |
100 µl |
EUR 277 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
Anti-Anti-SEPT5 Antibody antibody |
|
STJ114819 |
St John's Laboratory |
100 µl |
EUR 277 |
|
Description: This gene is a member of the septin gene family of nucleotide binding proteins, originally described in yeast as cell division cycle regulatory proteins. Septins are highly conserved in yeast, Drosophila, and mouse and appear to regulate cytoskeletal organization. Disruption of septin function disturbs cytokinesis and results in large multinucleate or polyploid cells. This gene is mapped to 22q11, the region frequently deleted in DiGeorge and velocardiofacial syndromes. A translocation involving the MLL gene and this gene has also been reported in patients with acute myeloid leukemia. Alternative splicing results in multiple transcript variants. The presence of a non-consensus polyA signal (AACAAT) in this gene also results in read-through transcription into the downstream neighboring gene (GP1BB; platelet glycoprotein Ib), whereby larger, non-coding transcripts are produced. |
Anti-Anti-SEPT7 Antibody antibody |
|
STJ116214 |
St John's Laboratory |
100 µl |
EUR 277 |
|
Description: This gene encodes a protein that is highly similar to the CDC10 protein of Saccharomyces cerevisiae. The protein also shares similarity with Diff 6 of Drosophila and with H5 of mouse. Each of these similar proteins, including the yeast CDC10, contains a GTP-binding motif. The yeast CDC10 protein is a structural component of the 10 nm filament which lies inside the cytoplasmic membrane and is essential for cytokinesis. This human protein functions in gliomagenesis and in the suppression of glioma cell growth, and it is required for the association of centromere-associated protein E with the kinetochore. Alternative splicing results in multiple transcript variants. Several related pseudogenes have been identified on chromosomes 5, 7, 9, 10, 11, 14, 17 and 19. |
A complete of 996 probably related research had been generated from the preliminary search, and 6 research had been discovered to fulfill all the inclusion standards and included in the last evaluate. The evaluate discovered that telehealth, eHealth, mHealth, telemedicine, and digital health file had been used digital health applied sciences to evaluate their impression on case detection, illness administration, and therapy end result of neglected tropical diseases. Mobile health was a possible digital health know-how for lymphatic filariasis affected person identification and mHealth, eHealth, and digital health information discovered to enhance the service entry, outcomes, and monitoring of visceral leishmaniasis at the neighborhood health system.
